What are the most valued startups in the longevity market?

Last updated: 9 June 2026

Download our beautiful pitch about the longevity market

market research pitch 2026 statistics longevity market

In our longevity market deck, you will find everything you need to understand the market

The longevity market is moving from niche science into a broader startup category that spans preventive healthcare, diagnostics, supplements, wearables, clinics, and age-related therapeutics.

This ranking is built to help readers track the most valuable longevity startups, using the latest reported or estimated valuations available in our database.

We update this list every month, so the ranking can reflect new rounds, public market changes, acquisitions, and fresh valuation signals.

And if you want to better understand this new industry, you can download our pitch covering the longevity market.

A quick summary table

Metric Value
Most valuable longevity startup Oura
Second most valuable longevity startup BioSplice Therapeutics
Median longevity startup valuation $92.5M
Share of longevity market valuation captured by the top 10 About 74.6%
Top longevity startup valuation vs. median About 119x
Median valuation-to-capital-raised ratio About 4.3x
Longevity startups valued at $1B+ 9
Market map chart showing top companies and startups in the longevity market

This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market

Top startups in the longevity market ranked by valuation

Here is an updated table that ranks the top startups in the longevity market based on their latest reported or estimated valuations.

If you want more detaild about their fundraising activity, you can check our list of the startups who have raised the most funding in the longevity market.

# Startup Name What They Do Current Valuation ($) Valuation Confidence Level Valuation Type Evidence Status Total Funding ($) Funding Confidence Level
1 Oura Smart ring health tracking $10.5B–$11.5B Strong Confidence Announced Private Round Valuation Observed $1.3B Partial Confidence
2 BioSplice Therapeutics Alternative splicing therapeutics $8.0B–$12.0B Partial Confidence Comparables-Based Estimate Estimated $778M Partial Confidence
3 Altos Labs Cellular rejuvenation therapeutics $5.0B–$7.0B Partial Confidence Proxy-Based Estimate Estimated $3.0B Full Confidence
4 NewLimit Cellular reprogramming longevity drugs $3.1B Full Confidence Announced Private Round Valuation Observed $755M Strong Confidence
5 Insilico Medicine AI drug discovery $2.6B Full Confidence Public Market Cap Observed $803M Partial Confidence
6 Function Health Preventive lab testing platform $2.3B–$2.7B Strong Confidence Announced Private Round Valuation Observed $351M Strong Confidence
7 Neko Health Preventive full-body health scans $1.6B–$2.0B Strong Confidence Announced Private Round Valuation Observed $325M Full Confidence
8 Retro Biosciences Reverses aging biology $1.8B Full Confidence Announced Private Round Valuation Observed $1.2B Partial Confidence
9 Calico Life Sciences Alphabet aging-biology research lab $1.0B–$2.5B Low Confidence Proxy-Based Estimate Estimated N/A in dataset Low Confidence
10 Loyal Dog longevity drugs $670M–$1.25B Partial Confidence Implied Valuation from Raise Implied $205M Partial Confidence
11 Juvenescence AI-enabled longevity therapeutics $550M–$1.0B Partial Confidence Implied Valuation from Raise Implied $333M Partial Confidence
12 Life Biosciences Cellular rejuvenation gene therapies $530M–$1.0B Partial Confidence Implied Valuation from Raise Implied $238M Partial Confidence
13 L-Nutra Fasting-mimicking nutrition programs $500M–$900M Strong Confidence Implied Valuation from Raise Implied $84M Strong Confidence
14 BioAge Labs Aging biology obesity therapeutics $659M Full Confidence Public Market Cap Observed $532M Full Confidence
15 Alzheon Alzheimer’s oral therapeutics $450M–$750M Partial Confidence Implied Valuation from Raise Estimated $206M Partial Confidence
16 Timeline Mitopure longevity supplements $400M–$700M Partial Confidence Implied Valuation from Raise Implied $75M Partial Confidence
17 Corsera Health Preventive cardiovascular RNAi medicines $400M–$670M Strong Confidence Implied Valuation from Raise Implied $80M Strong Confidence
18 Aeovian Pharmaceuticals Selective mTORC1 therapeutics $370M–$690M Partial Confidence Implied Valuation from Raise Implied $142M Strong Confidence
19 SciNeuro Pharmaceuticals Neurodegenerative disease therapeutics $350M–$660M Partial Confidence Implied Valuation from Raise Implied $153M Full Confidence
20 Gordian Biotechnology In-vivo aging drug discovery $300M–$500M Partial Confidence Implied Valuation from Raise Implied $60M Partial Confidence
21 Illimis Therapeutics Neuroimmune disease therapeutics $280M–$525M Partial Confidence Implied Valuation from Raise Implied $64M Partial Confidence
22 Nuritas AI-discovered bioactive peptides $280M–$525M Partial Confidence Implied Valuation from Raise Implied $113M Strong Confidence
23 Rejuveron Life Sciences Healthy-aging therapeutics platform $300M–$450M Partial Confidence Announced Private Round Valuation Observed $76M Partial Confidence
24 Cambrian Bio Builds longevity therapeutics $250M–$450M Low Confidence Comparables-Based Estimate Estimated $211M Partial Confidence
25 Viome Life Sciences Personalized microbiome health testing $250M–$400M Partial Confidence Implied Valuation from Raise Implied $243M Partial Confidence
26 Blueprint Consumer longevity protocol platform $240M–$400M Partial Confidence Implied Valuation from Raise Implied $60M Strong Confidence
27 Liom Non-invasive glucose wearable $240M–$390M Partial Confidence Implied Valuation from Raise Implied $79M Partial Confidence
28 Human Longevity Precision longevity diagnostics $280M–$340M Partial Confidence Proxy-Based Estimate Estimated $370M Strong Confidence
29 Arda Therapeutics Targeted pathogenic cell depletion $215M–$360M Partial Confidence Implied Valuation from Raise Implied $43M Full Confidence
30 Cellular Origins Automated cell therapy manufacturing $200M–$330M Partial Confidence Implied Valuation from Raise Implied $40M Full Confidence
31 Biograph Preventive longevity diagnostics clinics $180M–$340M Low Confidence Revenue or ARR Multiple Estimate Estimated $53.9M Low Confidence
32 Rubedo Life Sciences Senescent-cell therapeutics $180M–$300M Partial Confidence Implied Valuation from Raise Implied $52M Full Confidence
33 Jocasta Neuroscience a-Klotho cognitive therapeutics $175M–$290M Partial Confidence Implied Valuation from Raise Implied $35M Full Confidence
34 Neurable Everyday brain-computer interfaces $175M–$290M Partial Confidence Implied Valuation from Raise Implied $65M Partial Confidence
35 Elysium Health NAD+ longevity supplements $160M–$280M Low Confidence Revenue or ARR Multiple Estimate Estimated $66M Partial Confidence
36 Amplifier Therapeutics AMPK activator therapeutics $150M–$250M Partial Confidence Implied Valuation from Raise Implied $33M Strong Confidence
37 MindImmune Therapeutics Neuroinflammation Alzheimer’s therapies $150M–$250M Partial Confidence Implied Valuation from Raise Implied $36M Strong Confidence
38 resTORbio mTOR aging-disease therapeutics $170M Full Confidence Acquisition Value Observed $163M Full Confidence
39 Elevian Regenerative GDF11 therapeutics $100M–$220M Low Confidence Comparables-Based Estimate Estimated $61M Strong Confidence
40 Alkahest Plasma proteome aging therapies $140M–$150M Strong Confidence Acquisition Value Observed $41M Partial Confidence
41 Fountain Life Preventive longevity clinics $100M–$160M Partial Confidence Implied Valuation from Raise Implied $113M Strong Confidence
42 LyGenesis Organ-regeneration cell therapies $95M–$160M Partial Confidence Implied Valuation from Raise Implied $22M Strong Confidence
43 CohBar Mitochondrial peptide therapeutics $123M Full Confidence Public Market Cap Observed $63M Partial Confidence
44 Minovia Therapeutics Mitochondrial cell therapies $80M–$140M Low Confidence IPO or Listing Range Valuation Estimated Not provided Low Confidence
45 Tolerance Bio Thymus immune-tolerance therapies $80M–$135M Partial Confidence Implied Valuation from Raise Implied $20M Strong Confidence
46 Junevity siRNA cell reprogramming therapeutics $80M–$130M Partial Confidence Implied Valuation from Raise Implied $20M Full Confidence
47 Neuraly Neurodegenerative disease therapeutics $70M–$130M Low Confidence Proxy-Based Estimate Estimated $36M Full Confidence
48 Shift Bioscience AI cellular rejuvenation discovery $75M–$110M Partial Confidence Implied Valuation from Raise Implied $29M Partial Confidence
49 Oisin Biotechnologies Genetic anti-aging medicines $65M–$110M Partial Confidence Implied Valuation from Raise Implied $28M Partial Confidence
50 Booster Therapeutics Proteasome activator medicines $60M–$100M Partial Confidence Implied Valuation from Raise Implied $15M Full Confidence
51 Generation Lab Biological-age diagnostic platform $60M–$90M Partial Confidence Implied Valuation from Raise Implied $15M Partial Confidence
52 Grey Matter Neurosciences Alzheimer’s ultrasound headset $55M–$90M Partial Confidence Implied Valuation from Raise Implied $14M Full Confidence
53 Amphix Bio Peptide drugs for neurology $50M–$85M Strong Confidence Implied Valuation from Raise Implied $13M Strong Confidence
54 Radar Therapeutics Programmable mRNA therapeutics $45M–$85M Partial Confidence Implied Valuation from Raise Implied $13M Full Confidence
55 Morphoceuticals Bioelectric regenerative therapeutics $45M–$85M Partial Confidence Implied Valuation from Raise Implied $13M Partial Confidence
56 Circulate Health Therapeutic plasma exchange longevity $48M–$80M Partial Confidence Implied Valuation from Raise Implied $12M Full Confidence
57 Cirrus Therapeutics Ocular gene therapies $44M–$73M Partial Confidence Implied Valuation from Raise Implied $11M Full Confidence
58 GlycanAge Glycan biological age diagnostics $43M–$72M Partial Confidence Implied Valuation from Raise Implied $13M Full Confidence
59 Rejuvenation Technologies Telomerase mRNA therapeutics $35M–$80M Partial Confidence Implied Valuation from Raise Implied $11M Full Confidence
60 Edifice Health Inflammatory-age biomarker testing $35M–$80M Low Confidence Comparables-Based Estimate Estimated $12M Partial Confidence
61 Epiterna Ageing-slowing drug platform $35M–$75M Partial Confidence Implied Valuation from Raise Implied $11M Full Confidence
62 Everlab AI preventive healthcare $40M–$70M Partial Confidence Implied Valuation from Raise Implied $10M Full Confidence
63 Acorn Biolabs Follicle-cell cryopreservation $40M–$70M Partial Confidence Implied Valuation from Raise Implied $11M Strong Confidence
64 Modulo Bio Neuroimmune disease therapeutics $30M–$70M Partial Confidence Implied Valuation from Raise Implied $13M Strong Confidence
65 Deciduous Therapeutics Senescent-cell immunotherapies $35M–$55M Low Confidence Proxy-Based Estimate Estimated $17M Partial Confidence
66 NaNotics Subtractive nanomedicine platform $30M–$60M Low Confidence Comparables-Based Estimate Estimated $10M Partial Confidence
67 MitoRx Therapeutics Mitochondrial metabolic modulators $30M–$50M Partial Confidence Implied Valuation from Raise Implied $12M Partial Confidence
68 Vincere Biosciences Mitophagy Parkinson’s therapeutics $20M–$60M Low Confidence Proxy-Based Estimate Estimated Not provided Low Confidence
69 Repair Biotechnologies Cholesterol-degrading therapies $30M–$50M Partial Confidence Implied Valuation from Raise Implied $26M Partial Confidence
70 Cyclarity Therapeutics Cholesterol-damage reversal therapeutics $34M–$45M Strong Confidence Announced Private Round Valuation Observed $24M Strong Confidence
71 Cyclana Bio Endometriosis drug discovery platform $28M–$47M Partial Confidence Implied Valuation from Raise Implied $7M Full Confidence
72 Rejuvenate Bio Age-related gene therapies $25M–$50M Low Confidence Comparables-Based Estimate Estimated $10M Strong Confidence
73 Gero AI aging drug discovery $25M–$50M Low Confidence Comparables-Based Estimate Estimated $14M Partial Confidence
74 Turn Biotechnologies Cellular reprogramming therapies $20M–$50M Low Confidence Acquisition Value Estimated $30M Partial Confidence
75 Thymmune Therapeutics Thymic cell therapies $20M–$45M Low Confidence Comparables-Based Estimate Estimated $13M Partial Confidence
76 Biolytica AI longevity data platform $20M–$45M Partial Confidence Comparables-Based Estimate Estimated $6M Full Confidence
77 Vasa Therapeutics Cardiovascular aging drugs $20M–$40M Partial Confidence Implied Valuation from Raise Implied $6M Full Confidence
78 Tomorrow Bio Cryopreservation services $25M–$35M Partial Confidence Implied Valuation from Raise Implied $6M Full Confidence
79 AgelessRx Longevity telehealth prescriptions $22M–$37M Partial Confidence Implied Valuation from Raise Implied $5M Strong Confidence
80 clock.bio Stem-cell rejuvenation target discovery $21M–$35M Partial Confidence Implied Valuation from Raise Implied $10M Partial Confidence
81 NADMED NAD measurement kits $20M–$35M Partial Confidence Implied Valuation from Raise Implied $4M Partial Confidence
82 Matter Bio Preserves genome integrity $20M–$35M Low Confidence Implied Valuation from Raise Implied $7M Full Confidence
83 SENISCA RNA-based senotherapeutics $20M–$35M Partial Confidence Implied Valuation from Raise Implied $9M Strong Confidence
84 BE Therapeutics Brain tissue replacement $18M–$35M Low Confidence Proxy-Based Estimate Estimated $6M Low Confidence
85 Biopeak Longevity clinics and diagnostics $15M–$35M Strong Confidence Implied Valuation from Raise Implied $7M Strong Confidence
86 Celularity Placenta-derived cellular therapies $21M Full Confidence Public Market Cap Observed $393M Partial Confidence
87 Mito Health AI preventive healthcare $15M–$25M Partial Confidence Implied Valuation from Raise Implied $4M Strong Confidence
88 Unity Biotechnology Senolytic age-disease therapies $18M Full Confidence Public Market Cap Observed $307M Partial Confidence
89 Genflow Biosciences SIRT6 gene therapies $16M Full Confidence Public Market Cap Observed $8M Strong Confidence
90 Longevica Longevity therapeutics research platform $8M–$18M Low Confidence Proxy-Based Estimate Estimated $3M Partial Confidence
91 Bionic Health Preventive longevity care $5M–$20M Low Confidence Acquisition Value Estimated $3M Full Confidence
92 Tally Health Epigenetic age testing $5M–$20M Low Confidence Acquisition Value Estimated $10M Full Confidence
93 NOVOS Science-based longevity supplements $10M–$14M Partial Confidence Proxy-Based Estimate Estimated $3M Full Confidence
94 ImmuneAge Bio Immune rejuvenation platform $8M–$13M Partial Confidence Implied Valuation from Raise Implied $2M Strong Confidence
95 Leucadia Therapeutics Alzheimer’s device therapy $5M–$15M Low Confidence Proxy-Based Estimate Estimated Not provided Low Confidence
96 Decode Age Longevity microbiome diagnostics $7M–$11M Low Confidence Implied Valuation from Raise Implied $1.7M Low Confidence
97 Deep Longevity AI biological-age clocks $4M–$5M Strong Confidence Acquisition Value Observed Undisclosed Low Confidence
Chart comparing the 2026 size of the longevity market with other markets of similar size

This chart, featured in our longevity market deck, compares the 2026 size of the longevity market with other markets of similar size

Key valuation trends in the longevity market

Insights

  • The longevity market is highly concentrated. The top 10 startups represent about 75% of total valuation, which shows that most investor value is still clustered around a few platform leaders.
  • Oura is valued at about 119 times the median longevity startup in this dataset, which makes the smart ring company a clear outlier in consumer health tracking.
  • NewLimit, Function Health, and Neko Health together represent about $7.4B of valuation, which shows how strongly investors are pricing cellular reprogramming and preventive health platforms.
  • Function Health has raised $351M against a valuation range of $2.3B to $2.7B, giving the preventive lab testing company one of the strongest capital efficiency profiles among large longevity startups.
  • L-Nutra stands out with roughly $700M in midpoint valuation from $84M of funding, which suggests that consumer longevity nutrition can scale with less capital than drug development.
  • BioAge Labs shows the pressure facing public longevity biotech companies. BioAge Labs has raised $532M, but the public market value in this dataset is only about $659M.
  • Function Health, Neko Health, L-Nutra, and Biopeak together represent about $5.0B of valuation from only $767M of funding, which points to strong investor demand for preventive longevity models.
  • Therapeutics-focused longevity startups remain more capital intensive. NewLimit, BioAge Labs, Corsera Health, resTORbio, Amphix Bio, Cyclarity Therapeutics, and Genflow Biosciences represent about $4.6B of value from about $1.58B of funding.
Chart showing Function Health’s strategy in the longevity market

This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity

A few word about our methodology

As you can see, we built a database that ranks startups in the longevity market based on their current valuation.

Estimating startup valuations is not always straightforward. Many companies do not publicly disclose their valuation, and the available information can vary widely depending on the company and its stage.

To build this longevity startup ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.

Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed companies, or official acquisition prices.

When a longevity company is publicly listed, we use its current market capitalization as the reference valuation.

If a company was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.

When a startup recently raised capital but the valuation was not disclosed, we estimate the implied valuation using typical dilution levels for that stage of fundraising.

In some cases, we also estimate valuations using operating metrics such as revenue, ARR, patient traction, member growth, clinic expansion, or product adoption, combined with valuation multiples from comparable companies in the same market.

When direct financial data is not available, we may rely on carefully selected comparable startups and other signals such as hiring growth, investor quality, scientific progress, clinical milestones, or product traction.

All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by strong operating metrics and comparable company analysis.

We also carefully evaluate the age of every data point. Recent information carries more weight, while older data is treated cautiously and adjusted conservatively when necessary.

Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.

Because valuation data is not always fully public, each startup in the ranking is assigned a confidence level based on the reliability, recency, and consistency of the available evidence.

Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.

When confidence is lower, we take a more conservative approach by widening the valuation range. This helps reflect the uncertainty and increases the probability that the true valuation falls within the estimated range.

This reflects how we conduct all our research, including the work behind our report covering the longevity market.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

Chart showing the projected CAGR of the longevity market

This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups

Related blog posts

- The most recent news in the longevity market

- The most recent funding news in the longevity market

- The latest developments shaping the longevity market

- The evolution of funding activity in the longevity market

- The main fundraising trends in the longevity market

- How large is the longevity market in reality?

- The full range of business models in the longevity market

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog